Authors

Latest:

Dr Shusterman on a DNA Methylome Enrichment Platform for Early Detection of Solid Tumors

Michael Shusterman, MD, discusses findings from a retrospective study to determine the feasibility of a novel genome-wide methylome enrichment platform for the early detection of multiple solid tumors.

Mariana X. Byndloss, DVM, PhD

Latest:

Dr Byndloss on the Relationship Between the Gut Microbiome and GI Cancers

Mariana X. Byndloss, DVM, PhD, discusses how the gut microbiome influences human health, highlighting the relationship between the gut microbiome and a person’s risk for developing gastrointestinal cancers, as well as characteristics of a healthy gut microbiome.

Rutgers Cancer Institute

Latest:

Expert Commentary: Insights into Cancer Mutation Patterns

Researchers at Rutgers Cancer Institute of New Jersey provided commentary on how changes in the structure of DNA influence the mutation patterns in cancer.

Alexander van Akkooi, MD, PhD, FRACS

Latest:

Dr Akkooi on Pathologic Review Discrepancies and Overtreatment Risks in Metastatic Melanoma

Alexander C.J. Van Akkooi, MD, PhD, FRACS, discusses how discrepancies in local and central pathologic review can expose patients to potential toxicities associated with overtreatment for metastatic melanoma.

Courtney Coschi, MD, PhD

Latest:

Is War a Good Metaphor for Cancer Care?

The National Cancer Act of 1971 introduced the concept of a “war on cancer,” which has since affected the language we use when discussing the disease.

Jarushka Naidoo, MD, M.B.B.Ch.

Latest:

Combination Chemotherapy and Immunotherapy for Advanced NSCLC

Experts review data updates on chemotherapy / immunotherapy combination treatments in advanced NSCLC.

Sumanta K. Pal, MD

Latest:

Dr Pal on Outcomes With the Use of Zanzalintinib in Relapsed/Refractory ccRCC

Sumanta Kumar Pal, MD, FASCO, discusses outcomes with the use of zanzalintinib in patients with relapsed/refractory clear cell renal cell carcinoma.

Jiye Liu, PhD

Latest:

Dr Liu on Epigenetic Regulation of CD38/CD48 in Multiple Myeloma

Jiye Liu, PhD, discusses epigenetic regulation of CD38/CD48 in multiple myeloma.

Reena Salgia, MD, Henry Ford Health System

Latest:

Hepatocellular Carcinoma: Practical Implications of Emerging Data

Mehmet K. Samur, PhD

Latest:

Dr. Samur on the Evolving Treatment Landscape in Multiple Myeloma

Mehmet K. Samur, PhD, discusses the evolving treatment landscape in multiple myeloma.

Lynne E. Dettore, MA

Latest:

A Miracle Maker in Pediatric Hematologic Cancers

A love of collaborating with colleagues from around the globe and a fiery passion to help children diagnosed with cancer led Ching-Hon Pui, MD, to dramatically improve outcomes in pediatric oncology.

Bartosz Chmielowski, MD

Latest:

Dr Chmielowski on the Rationale for Investigating Oncolytic Viruses in Melanoma

Bartosz Chmielowski, MD, PhD, discusses the rationale for investigating oncolytic viruses in melanoma.

Radhika Poojari, PhD

Latest:

Cetuximab–Radionuclide Functionalized Polymeric Nanocomplexes: A Radiopharmaceutical Perspective for Liver Cancer

Liver cancer is a highly vascularized and one of the most drug resistant forms of solid tumors.

Robin Foa, MD, Sapienza University

Latest:

MRD as a Prognostic Indicator in Children and Young Adults with Very High-Risk ALL

Doug Smith, MD, provides context for the AALL1131: a phase III randomized trial for newly diagnosed high risk b-precursor acute lymphoblastic leukemia (ALL).

Alessandra Larocca, MD, PhD

Latest:

Dr. Larocca on Recent Advancements in R/R Multiple Myeloma

Alessandra Larocca, MD, PhD, discusses recent advancements in relapsed/refractory multiple myeloma.

Chau Dang, MD, Memorial Sloan Kettering Westchester

Latest:

Dr. Dang on the Design of the BERENICE Trial in HER2+ Breast Cancer

Chau T. Dang, MD, discusses the rationale of the phase 2 BERENICE trial in early-stage HER2-positive breast cancer.

Kyle Lowry

Brian M. Andersen, MD, PhD

Latest:

Will Immunotherapy Become a Standard of Care for Glioblastoma?

Given the current lack of positive phase 3 immunotherapy trials for glioblastoma, a misconception held by oncologists and neuro-oncologists is that immunotherapy has no place in this malignancy.

Mary Anne Fenton, MD

Latest:

Dr Fenton on Findings from the DESTINY-Breast02 Trial in HER2+ Breast Cancer

Mary Anne Fenton, MD, discusses findings from the phase 3 DESTINY-Breast02 trial in patients with HER2-positive metastatic breast cancer.

Yoshie Umemura, MD

Latest:

Dr Umemura on the Development of ONC201 in H3K27M-Mutant Diffuse Midline Glioma

Yoshie Umemura, MD, discusses the development of ONC201 in patients with H3K27M-mutated diffuse midline glioma.